Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics

Clinical Drug Investigation
Viktoria MoschettiMichael Desch

Abstract

Schizophrenia and Alzheimer's disease are characterised by abnormalities in glutamatergic pathways related to N-methyl-D-aspartate receptor hypofunction. Glycine is an N-methyl-D-aspartate receptor co-agonist; inhibition of glycine transporter 1 may improve N-methyl-D-aspartate receptor function. This phase I, randomised, two-part study evaluated the safety, tolerability and pharmacokinetic profile of BI 425809, a novel glycine transporter 1 inhibitor, in healthy male and female volunteers. Part 1 evaluated BI 425809 10, 25, 50 or 75 mg once daily or 75 mg twice daily in young subjects, and 25 mg or 50 mg once daily in elderly subjects. Each dose group comprised 12 subjects who received BI 425809 (n = 9) or placebo (n = 3) for 14 days (day 1: single dose; days 4-14: multiple dosing). Part 2 compared pharmacokinetic profiles in 12 subjects who received a single dose of BI 425809 25 mg in the morning and evening. Pharmacokinetic profiles were similarly shaped for all dose groups. Median time to maximum plasma concentration was 3.0-4.5 h with steady state being reached between days 6 and 10. Pharmacokinetic parameters demonstrated dose linearity at the predicted therapeutic exposure range of BI 425809 ≤ 25 mg once daily, but incre...Continue Reading

References

May 3, 1997·Schizophrenia Research·D I VelliganA L Miller
Sep 5, 2001·The American Journal of Psychiatry·D C Goff, J T Coyle
Aug 27, 2004·Schizophrenia Research·Jovier D EvansSandra Tunis
Jan 22, 2011·The Open Medicinal Chemistry Journal·Kenji Hashimoto
Nov 25, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Deepak Cyril D'SouzaJacques Schipper
Jun 1, 2012·British Journal of Pharmacology·Wojciech Danysz, Chris G Parsons
Jul 17, 2012·Neuropharmacology·Graham L CollingridgeDavid E Jane
Nov 3, 2012·British Journal of Clinical Pharmacology·Marieke Liem-MoolenaarJoop M A van Gerven
Oct 22, 2013·JAMA : the Journal of the American Medical Association·UNKNOWN World Medical Association
Oct 24, 2013·Cutaneous and Ocular Toxicology·Chang-Ning LiuChris Somps

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02337283

Software Mentioned

SAS
Phoenix WinNonlin

Related Concepts

Related Feeds

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.